Economic burden of the persistent morbidity of nodding syndrome on caregivers in affected households in Northern Uganda

Latio, Lugala Samson Yoane; Nam, Nguyen Hai; Shah, Jaffer; Smith, Chris; Sakai, Kikuko; Shaban, Kato Stonewall; Idro, Richard; Nishi, Makoto; Huy, Nguyen Tien; Hamano, Shinjiro; Moji, Kazuhiko

doi:10.1371/journal.pone.0238643

Cited by 9 publications

(9 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DMC included the costs of visits, purchase of medicine, Magnetic Resonance Imaging (MRI), laboratory tests, hospitalization, and physiotherapy, where the unit price of each item and the rates of their use per year are reported in Table 2 . It is worth noting that the unit price of each item is based on the annual tariff announced by the Ministry of Health and Medical Education [ 47 ]. Furthermore, the rate of using each service was calculated based on the experts’ opinion.…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Rezaee

Morowvat

Poursadeghfard

et al. 2022

BMC Health Serv Res

View full text Add to dashboard Cite

Introduction Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths of the nerve cells in the brain and spinal cord, which are responsible for communication, are destroyed and cause physical signs and symptoms. According to studies, anti-CD20 monoclonal antibodies have significant results in the treatment of this disease. Thus, the aim of the present study was to determine the cost-effectiveness of rituximab against natalizumab in the patients with RRMS in southern Iran in 2020. Methods This is an economic evaluation including cost-effectiveness analysis in which the Markov model with a lifetime horizon was used. The study sample consisted of 120 patients randomly selected from among those referred to the MS Association and the Special Diseases Unit of Shiraz University of Medical Sciences. In this study, the costs were collected from a societal perspective, and the outcomes were obtained in the form of Quality Adjusted Life Years (QALY) and the mean relapse rate. The TreeAge pro 2020 and Excel 2016 software were used for data analysis. Results The comparative study of rituximab and natalizumab showed that the patients receiving rituximab had lower costs ($ 58,307.93 vs. $ 354,174.85) and more QALYs (7.77 vs. 7.65). In addition, the incidence of relapse by rituximab was lower compared to natalizumab (1.15 vs. 2.57). The probabilistic one-way sensitivity analysis showed the robustness of the results. The scatter plots also showed that rituximab was more cost-effective for the patients in 100% of the simulations for the threshold of < $ 37,641. Discussion and conclusion According to the results of this study, rituximab had higher cost-effectiveness than natalizumab. Therefore, it could be a priority for RRMS patients compared to natalizumab because it reduced treatment costs and increased effectiveness.

show abstract

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Rezaee

Morowvat

Poursadeghfard

et al. 2022

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…The DNMC and IC data were collected based on the patients' self-report through face-to-face interviews or telephone calls. The human capital approach was used to calculate the IC [27,28]. In addition, all costs were calculated based on the tariffs of 2020 and converted into international dollars (purchasing power parity (PPP)) at the exchange rate of 1 dollar = 22057 Rials [29].…”

Section: Treatment Costsmentioning

confidence: 99%

Cost-Effectiveness Analysis Of Plant Versus Antibiotic Regimens In Treating Patients With Helicobacter Pylori (H. Pylori) Infection In The South Of Iran

Faramarzi

Khajoei

Lotfi

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Helicobacter pylori infection is highly prevalent worldwide and affects more than half of the world's population. A variety of treatment regimens to eliminate H. pylori infection have been evaluated, but choosing the best treatment method that results in the most eradication at the lowest cost is one of the challenges facing physicians. Therefore, the present study aimed at analyzing the cost-effectiveness of using different methods to treat H. pylori in southern Iran. Methods: This study was a cost-effectiveness analysis conducted on 132 patients with H. pylori who referred to Shahid Motahari Clinic in Shiraz. The study was carried out in 2020 to evaluate two drug treatment strategies, including antibiotics (pantoprazole 40 mg, Bismuth subcitrate 108 mg, tetracycline 500 mg, and metronidazole 200 and 400 mg) and plants (Supermint Barij soft capsules 20 mg, Alium S garlic tablets 400 mg, and Green Teadin (green tea) tablets 500 mg). The patients were randomly divided into two groups, 64 of whom received an antibiotic regimen and 68 patients given a plant regimen. The success rate of clinical trials in each treatment method was determined as the clinical outcome. This study was conducted from a community perspective and therefore, direct and indirect costs were included. A data collection form was also used to collect the cost and effectiveness data. In addition, a one-way sensitivity analysis was performed to measure the robustness of the results. The data were analyzed using TreeAge Pro 2011 and Excel 2016 software. Results: The results showed that antibiotic treatment was cheaper and more effective than plant treatment and was the dominant strategy. The mean costs in the antibiotics and plant groups were $446.14 and $477.81, respectively, and the effectiveness was 0.625% and 0.382%. In addition, the one-way sensitivity analysis confirmed the robustness of the study results. Conclusion: The results showed that the use of antibiotics was a cost-effective and dominant strategy compared to plant treatment and could be suggested as a better alternative to a wide range of patients with Helicobacter pylori infection.

show abstract

“…DNMC and IC data were gathered through self-reported patients' companions by face-to-face interviews or telephone calls. We used the human capital approach for calculating the IC (23,24). In addition, all costs were calculated based on the tariffs of 2020 and exchanged into international dollar (purchasing power parity) at the exchange rate of 1 dollar equals 31317 Rials (25).…”

Section: Treatment Costsmentioning

confidence: 99%

Cost Effectiveness Analysis of Home-Based Phototherapy Versus Hospital-Based Phototherapy for Treatment of Neonatal Hyperbilirubinemia in shiraz, Iran

Kavosi

Mozafari

Rezaee

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Neonatal jaundice is the most common cause of hospitalization of mature and healthy infants. Phototherapy is the most common treatment for the rise in indirect bilirubin. Hospitalization of infants has complications such as hospital infections, separation of the mother from the baby, occupying hospital beds and high cost of hospitalization. Since phototherapy is possible at home and by home care centers, this study was conducted to analyze the cost-effectiveness of phototherapy at home versus phototherapy in hospital in Shiraz in 2021. Methods This research is a complete economic evaluation of cost-effectiveness that was conducted cross-sectionally from March to August 2021 in Hafez and Hazrat Zeinab hospitals and Parseh and Ava Gostar home care centers in Shiraz. The study population included all neonates who were admitted to these centers with a diagnosis of jaundice for phototherapy. 180 neonates with jaundice in the two groups of hospital and home care were included in the study. The effectiveness index for this study was the average daily decrease in total bilirubin. We made use of cost and effectiveness forms to collect the required information. The results were presented in the form of incremental cost-effectiveness ratio (ICER) and one-way and probabilistic sensitivity analysis was used to measure the strength of the study results. TreeAge pro2020, Excel 2019 and Spss18 were used to analyze the collected data. Results The results showed that the average cost of phototherapy at home and hospital were $ 196.52 and $ 397.85, respectively, and the average effectiveness was 0.39 and 0.36, respectively. Therefore, according to the results, phototherapy at home is more cost-effective than phototherapy in the hospital. In addition, the results of one-way and probabilistic sensitivity analysis showed the strength of the research results. Conclusion Phototherapy at home is a more cost-effective option than phototherapy in the hospital. Therefore, it can be suggested to insurance organizations as well as service providers to prioritize phototherapy at home to be included in the basic insurance package.

show abstract

Economic burden of the persistent morbidity of nodding syndrome on caregivers in affected households in Northern Uganda

Cited by 9 publications

References 43 publications

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Cost-Effectiveness Analysis Of Plant Versus Antibiotic Regimens In Treating Patients With Helicobacter Pylori (H. Pylori) Infection In The South Of Iran

Cost Effectiveness Analysis of Home-Based Phototherapy Versus Hospital-Based Phototherapy for Treatment of Neonatal Hyperbilirubinemia in shiraz, Iran

Contact Info

Product

Resources

About